US FDA Vaccines Adcomm May Be Called To Review COVID-19 Vaccine Strain Changes

CBER Director Peter Marks said the VRBPAC may need to opine on the immunogenicity data gathered for vaccine updates.

CBER's Peter Marks is interviewed in his basement for the FDA/CMS Summit 2020. (screenshot)
Peter Marks said that the source of anaphylactic reactions to the vaccines still is unknown, but studies are ongoing. • Source: screenshot

Future vaccine tweaks to cover coronavirus mutations may require a public meeting even in a streamlined US Food and Drug Administration emergency use authorization process.

Worries about coronavirus variants have raised questions about the efficacy of the two available vaccines against them. Should the virus...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet